Core Viewpoint - The approval of Weisheng Pharmaceutical's long-acting growth hormone injection marks a significant advancement in the domestic growth hormone market, addressing compliance issues associated with daily injections for children with growth hormone deficiency [1][2]. Industry Overview - The Chinese growth hormone market has surged from 4 billion yuan in 2018 to 11.6 billion yuan in 2023, with a compound annual growth rate (CAGR) of 23.9%, and is projected to reach 28.6 billion yuan by 2030 [1]. - The long-acting growth hormone market is expected to surpass short-acting products within two years and capture 80% of the total market by 2030 [1]. Competitive Landscape - Existing competitors in the long-acting growth hormone space include Changchun High-tech's Jinsai Pharmaceutical, Teva Biopharma, and Novo Nordisk, with Jinsai and Teva's products already included in the national medical insurance directory for 2025 [2]. - Weisheng's long-acting growth hormone is the only one clinically proven to outperform daily formulations, offering both long-lasting effects and maintaining the natural structure of growth hormone molecules [2]. Product Advantages - Weisheng's long-acting growth hormone can be stored at room temperature below 30 degrees Celsius for up to six months, enhancing convenience for patients compared to other products that require refrigeration [2]. - The pricing strategy for Weisheng's product is anticipated to be higher than currently insured long-acting growth hormones, which have seen significant price reductions due to insurance coverage [3]. Commercial Strategy - Weisheng has partnered with Anke Bio to leverage its extensive commercial experience in the growth hormone sector, focusing on coastal provinces while Anke manages other regions [3]. - The company aims to target private clinics, where a significant portion of growth hormone treatments occur, to reach potential patients effectively [4]. Future Developments - There is potential for the introduction of even longer-acting monthly formulations, with ongoing clinical trials for a novel ultra-long-acting growth hormone [4].

Core Viewpoint - The vaccine sector is experiencing strong performance due to the emergence of Nipah virus cases in India, leading to increased investment in related biopharmaceutical ETFs [1][3]. Group 1: Market Performance - The biopharmaceutical ETF Huatai (159839) saw a significant increase of 2.13% with a trading volume exceeding 60 million yuan, marking a 133% increase compared to the previous period [1]. - The ETF received a net subscription of 16.5 million shares today, accumulating nearly 40 million yuan in the last five days [1]. - Major component stocks of the ETF showed positive performance, with Zhifei Biological rising nearly 15%, Watson Bio increasing over 11%, and Hualan Biological up nearly 7% [3]. Group 2: Nipah Virus Impact - Five confirmed cases of Nipah virus infection have been reported in West Bengal, India, including healthcare workers, with nearly 100 individuals under home quarantine [3]. - The Nipah virus can attack the lungs and brain, with symptoms including fever, headache, drowsiness, and confusion, and a mortality rate of over 40% [3]. - There is currently no specific vaccine or effective treatment for the Nipah virus [3]. Group 3: Vaccine Development and Innovation - Hualan Biological received approval for clinical trials of its recombinant shingles vaccine, while Zhifei Biological's CA111 injection has entered Phase I clinical trials [7]. - The vaccine industry is focusing on technological upgrades and exploring new markets, particularly in the Middle East [8]. - The growth of the vaccine sector is expected to be driven by the increasing immunization needs of the aging population, shifting focus from children to a broader demographic [8]. Group 4: mRNA Vaccine Developments - Recent positive clinical data from mRNA vaccine leaders indicate a breakthrough development window for therapeutic cancer vaccines [9]. - mRNA technology offers significant advantages over traditional methods, including rapid production capabilities and enhanced safety profiles [9].

Core Viewpoint - Changchun High-tech announced that its subsidiary, Jinsai Pharmaceutical, received approval for clinical trials of GenSci145 tablets, a novel selective PI3Kα inhibitor targeting PIK3CA mutation in advanced or metastatic solid tumors [1][2] Group 1: Product Development - GenSci145 is a first-class innovative chemical drug designed for treating locally advanced or metastatic solid tumors with PIK3CA mutations [1] - PIK3CA mutations are significant in breast cancer, accounting for 30%-40% of cases, and are crucial for tumor growth and resistance to treatments [1] Group 2: Clinical Need and Advantages - Existing PI3Kα inhibitors have poor targeting and can cause side effects like hyperglycemia, rash, and diarrhea, affecting long-term treatment adherence [2] - GenSci145 has shown selective inhibitory activity against various PIK3CA hotspot mutations and good blood-brain barrier penetration without traditional side effects, indicating its potential to meet clinical needs for patients with PIK3CA mutations and brain metastases [2] Group 3: Company Commitment - The company will actively advance the research and development of GenSci145 and comply with information disclosure obligations regarding project progress [2]

Core Viewpoint - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical, received approval from the National Medical Products Administration for the clinical trial of GenSci145 tablets, a new selective PI3Kα inhibitor for treating advanced or metastatic solid tumors with PIK3CA mutations [1]. Group 1 - Changchun Jinsai Pharmaceutical has developed GenSci145 tablets, classified as a first-class innovative chemical drug [1]. - The drug is intended for patients with locally advanced or metastatic solid tumors carrying PIK3CA mutations [1].

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of GenSci145 tablets, a novel selective PI3Kα inhibitor intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations [1] Group 1 - The clinical trial approval for GenSci145 marks a significant milestone for Jinsai Pharmaceutical in the development of innovative drugs [1] - GenSci145 is classified as a Class 1 innovative chemical drug, indicating its potential to address unmet medical needs in oncology [1] - The drug targets specific mutations (PIK3CA) associated with certain types of cancer, highlighting its specialized therapeutic application [1]

证券之星消息，1月23日生物制品板块较上一交易日上涨1.45%，沃森生物领涨。当日上证指数报收于 4136.16，上涨0.33%。深证成指报收于14439.66，上涨0.79%。生物制品板块个股涨跌见下表： 从资金流向上来看，当日生物制品板块主力资金净流入1.98亿元，游资资金净流出2.72亿元，散户资金净 流入7437.55万元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300142 沃森生物 | | 1.34 Z | 9.80% | -8331.39万 | -6.11% | -5032.70万 | -3.69% | | 000661 | 长春高新 | 5154.65万 | 8.00% | -1654.92万 | -2.57% | -3499.73万 | -5.43% | | 002252 上海莱士 | | 4593.03万 | 13.12% | -2426.69万 | - ...

Core Viewpoint - Changchun Gaoxin (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of GenSci145 tablets, a novel selective PI3Kα inhibitor intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations [1] Group 1 - Jinsai Pharmaceutical's GenSci145 tablets are classified as a Class 1 innovative chemical drug [1] - The drug is specifically developed for patients carrying PIK3CA mutations [1] - The approval marks a significant milestone in the company's drug development pipeline [1]

证券代码：000661 证券简称：长春高新 公告编号：2026-004 长春高新技术产业（集团）股份有限公司 关于子公司 GenSci145 片境内生产药品注册临床试验申请 获得批准的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 二、药品的其它情况 GenSci145 片是金赛药业开发的一款新型突变选择性 PI3Kα抑制剂，属 1 类创新型化学药品，拟用于携带 PIK3CA 突变的局部晚期或转移性实体瘤的治疗。 PIK3CA 基因突变在乳腺癌中占 30%～40%，是乳腺癌发生和进展的重要因 素。PIK3CA 基因编码 PI3Kα的催化亚基 p110α是 PI3K-AKT-mTOR 信号通路 的核心，PIK3CA 基因突变可导致该通路异常激活，促进肿瘤细胞的生长和抗凋 亡能力，并且可导致乳腺癌内分泌治疗、化疗和靶向治疗的耐药。对于携带 PIK3CA 突变的患者，开发针对性的 PI3K 通路抑制剂，将有助于改善患者的疗 效和预后。 近日，长春高新技术产业（集团）股份有限公司（以下简称"公司"）子公 司——长春金赛药业有限责任公司（以下简称"金赛药业"）收到 ...

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for the clinical trial application of its drug GenSci145 tablets, which is a novel selective PI3Kα inhibitor intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations [1]. Group 1 - Jinsai Pharmaceutical's GenSci145 tablets are classified as a Class 1 innovative chemical drug [1]. - The drug is specifically designed for patients carrying PIK3CA mutations [1]. - The approval marks a significant milestone in the development of targeted therapies for specific cancer mutations [1].

格隆汇1月23日丨长春高新(000661.SZ)公布，子公司——长春金赛药业有限责任公司（简称"金赛药 业"）收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci145片的境内 生产药品注册临床试验申请获得批准。GenSci145片是金赛药业开发的一款新型突变选择性PI3Kα抑制 剂，属1类创新型化学药品，拟用于携带PIK3CA突变的局部晚期或转移性实体瘤的治疗。 ...